
Acasti Pharma Inc.
ACST
NSC

Sector: Healthcare
Industry: Biotechnology
0.93
USD
-0.02
(-2.56%)
Optionable: No Market Cap: 43 M 90-day average vol: 154,561
Previous close: 0.95 Open: 0.9215 Bid: 0.97 Ask: 0.97
52 week range
0.39 2.94
Last updated: Monday 23rd May 2022
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 0.36 |
PE Ratio (TTM) | -2.90 |
Book Value per Share ($) | 3.25 |
5 Year PE Range | NA , NA |
Returns
7 Day Return | -0.97% | |
1 Month Return | -15.85% | |
3 Month Return | -15.85% | |
1 Year Return | -76.92% | |
3 Year Return | -87.22% | |
5 Year Return | -90.82% | |
YTD Return | -26.53% |
Risk
Financial Health
Technicals
RSI (14 Day) | 38.89 |
14 Day SMA ($) | 0.96 |
14 Day EMA ($) | 0.96 |
Money Flow Index | 74.11 |
Average True Range | 0.07 |
50 Day SMA ($) | 1.09 |
200 Day SMA ($) | 1.32 |
ADX | 12.06 |
MACD | -0.05 |
Growth
Free Cash Flow QoQ Growth | -24.90% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -400.00% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
Return on Assets TTM (%) | -15.97 |
Profit Margin TTM (%) | -18944.3 |
Return on Equity TTM (%) | -16.88 |
Return on Capital TTM (%) | -17.21 |
Interest Coverage Ratio | 45.50 |
Gross Margin TTM (%) | 65.2 |
Acasti Pharma Celebrates Rare Disease Day
Yahoo Finance 2/28/2022
New Strong Sell Stocks for February 23rd
Yahoo Finance 2/23/2022
Acasti Pharma Inc. CEO, Jan D'Alvise, Is Featured on The Stock Day Podcast
Yahoo Finance 2/22/2022
Acasti Pharma Inc.'s (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript
Seeking Alpha 2/14/2022
Acasti Pharma GAAP EPS of -$0.09 misses by $0.01
Seeking Alpha 2/14/2022
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022
Yahoo Finance 2/14/2022
Acasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference Call
Yahoo Finance 2/7/2022
Acasti Pharma (ACST) Investor Presentation - Slideshow
Seeking Alpha 1/10/2022
Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference
Yahoo Finance 1/3/2022
BLITF Stock: 7 Thing to Know About Mobile Gaming Play i3 Interactive as Shares Rocket Today
Yahoo Finance 12/23/2021
ACST Stock Price Predictions: Why One Analyst Sees Acasti Rocketing to $6
Yahoo Finance 12/22/2021
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Yahoo Finance 12/22/2021
Acasti Pharma jumps 21% on new Outperform rating at Oppenheimer with PT of $6
Seeking Alpha 12/22/2021
Market Sentiment Around Loss-Making Acasti Pharma Inc. (CVE:ACST)
Yahoo Finance 12/21/2021
Acasti says candidate for subarachnoid hemorrhage met main goals in pivotal PK study
Seeking Alpha 12/2/2021
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104
Yahoo Finance 12/2/2021
Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd
Yahoo Finance 11/24/2021
Acasti Pharma Announces Annual Stock Option Grants
Yahoo Finance 11/12/2021
NA |
---|
could not broadcast input array from shape (20) into shape (0) |
---|
ACST Income Statement
Annual
Feb-12 | Feb-13 | Feb-14 | Feb-15 | Feb-16 | Mar-17 | Mar-18 | Mar-19 | Mar-20 | |
---|---|---|---|---|---|---|---|---|---|
Total revenues | 10475 | 707395 | 450159 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of sales | -666656 | -252658 | -1 M | -2 M | -2 M | -2 M | -3 M | -2 M | -2 M |
Gross operating profit | 5368 | 310451 | 238572 | -235091 | -60082 | 0 | 0 | 0 | 0 |
Selling Gen & administrative expense | 3 M | 4 M | 5 M | 4 M | 2 M | 3 M | 4 M | 4 M | 8 M |
Research & development expense | 3 M | 3 M | 6 M | 9 M | 6 M | 6 M | 16 M | 29 M | 16 M |
Operating income | -7 M | -7 M | -11 M | -12 M | -7 M | -8 M | -20 M | -34 M | -24 M |
floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other income net | -22401 | 41823 | 246396 | 11 M | 2 M | -174717 | -376000 | -5 M | -1 M |
Pre-tax Income (EBT) | -7 M | -7 M | -10 M | -2 M | -5 M | -9 M | -22 M | -39 M | -26 M |
Income taxes | 0 | 0 | 0 | 0 | 0 | -96732 | 0 | 0 | 0 |
Net income from total operations | -7 M | -7 M | -12 M | -2 M | -5 M | -8 M | -22 M | -39 M | -26 M |
Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total net income | -7 M | -7 M | -10 M | -2 M | -5 M | -8 M | -22 M | -39 M | -26 M |
Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Net income available for common | -7 M | -7 M | -12 M | -2 M | -5 M | -8 M | -22 M | -39 M | -26 M |
Depreciation | 671763 | 649601 | 2 M | 2 M | 2 M | 2 M | 3 M | 2 M | 2 M |
Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating income before depreciation (EBITDA) | -6 M | -6 M | -9 M | -10 M | -3 M | -6 M | -18 M | -37 M | -23 M |
Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Basic EPS total | -1.01 | -0.88 | -1.4 | -0.16 | -0.44 | -0.76 | -1.23 | -0.73 | -2.4 |
Diluted EPS total | -1.01 | -0.88 | -1.4 | -0.16 | -0.44 | -0.76 | -1.23 | -0.73 | -2.4 |
Top MarketXLS Rank stocks
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!